This website uses cookies
Read our Privacy policy and Terms of use for more information.
ONE-TIME NEW-SUBSCRIBER WELCOME OFFER
Save $50 from the regular $250 annual price on this new-subscriber welcome page.
✓ Full Tracker, Scout and Watchlist access
✓ Every member-only company review and 25-gate score
✓ Valuation context, human evidence and the next milestone to watch
This welcome offer is shown to new subscribers. Standard pricing and renewal terms are shown before payment.
No thanks, continue to the free welcome page
Full access to Tracker, Scout and Watchlist
Every company we cover in one place, with the tools we use to organize and compare them.
Entry dates, framework scores and valuation context
See when we first flagged a name, how it scores against our framework, and what it may be worth.
Plain-English science, no jargon
Every mechanism and technology explained clearly, so you understand what a company is actually doing.
Human evidence, clearly separated
We separate human trial results from animal, lab and biomarker findings, so you always know how strong the evidence really is.
The next milestone that could change the case
We flag the specific catalyst or data readout to watch next, and what it would mean if it hits or misses.
Longevity biotech is developing faster than most people know how to evaluate it. Premium lets you follow the record transparently, seeing our calls, our reasoning and the outcomes as they happen, not after the fact.
Built by Eric Pemper after more than 25 years building companies and selling most of his business in 2026.
Get instant access to the Tracker, Scout, Watchlist and every member-only section, plus full history on every company we cover.
Get EverLife Premium for $200EverLife provides independent, impersonal educational research. It is not investment or medical advice. Biotechnology programs often fail, and securities can lose all value. Read the full disclosure